These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6831170)

  • 1. Calcium excretion (CaE) in metastatic breast cancer.
    Campbell FC; Blamey RW; Woolfson AM; Elston CW; Hosking DJ
    Br J Surg; 1983 Apr; 70(4):202-4. PubMed ID: 6831170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium excretion in metastatic prostatic carcinoma.
    Grainger R; Reda M; Fitzpatrick JM
    Br J Urol; 1984 Dec; 56(6):687-9. PubMed ID: 6534491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy.
    Ralston SH; Fogelman I; Gardiner MD; Boyle IT
    Br Med J (Clin Res Ed); 1984 May; 288(6428):1405-8. PubMed ID: 6426577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease.
    Coleman RE; Houston S; James I; Rodger A; Rubens RD; Leonard RC; Ford J
    Br J Cancer; 1992 May; 65(5):766-8. PubMed ID: 1586605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of malignant hypercalcaemia in carcinoma of the breast.
    Percival RC; Yates AJ; Gray RE; Galloway J; Rogers K; Neal FE; Kanis JA
    Br Med J (Clin Res Ed); 1985 Sep; 291(6498):776-9. PubMed ID: 3929936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypercalcaemia and metastatic bone disease: is there a causal link?
    Ralston S; Fogelman I; Gardner MD; Boyle IT
    Lancet; 1982 Oct; 2(8304):903-5. PubMed ID: 6126753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyproline excretion in patients with breast cancer and response to treatment.
    Powles TJ; Leese CL; Bondy PK
    Br Med J; 1975 Apr; 2(5964):164-6. PubMed ID: 1125725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of hydroxyproline excretion to bone metastasis in breast cancer.
    Gielen F; Dequeker J; Drochmans A; Wildiers J; Merlevede M
    Br J Cancer; 1976 Sep; 34(3):279-85. PubMed ID: 974001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
    Body JJ; Dumon JC; Gineyts E; Delmas PD
    Br J Cancer; 1997; 75(3):408-12. PubMed ID: 9020487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyridinium crosslinks as markers of bone resorption in patients with breast cancer.
    Paterson CR; Robins SP; Horobin JM; Preece PE; Cuschieri A
    Br J Cancer; 1991 Nov; 64(5):884-6. PubMed ID: 1931610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postabsorptive urinary hydroxyproline test in patients with metastatic bone disease from breast cancer.
    Niell HB; Palmieri GM; Neely CL; McDonald MW
    Arch Intern Med; 1981 Oct; 141(11):1471-3. PubMed ID: 7283558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parathyroid hormone related protein and hypercalcaemia in breast cancer.
    Bundred NJ; Ratcliffe WA; Walker RA; Coley S; Morrison JM; Ratcliffe JG
    BMJ; 1991 Dec; 303(6816):1506-9. PubMed ID: 1782489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
    Coleman RE; Rubens RD
    Br J Cancer; 1987 Oct; 56(4):465-9. PubMed ID: 3689664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulation of calcium reabsorption observed in advanced breast cancer patients with hypercalcemia and multiple bone metastases.
    Kimura S; Adchi I; Yamaguchi K; Suzuki M; Shimada A; Sato Y; Nagaoka K; Abe K
    Jpn J Cancer Res; 1985 Apr; 76(4):308-14. PubMed ID: 2989061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urine calcium and serum ionized calcium, total calcium and parathyroid hormone concentrations in the diagnosis of primary hyperparathyroidism and familial benign hypercalcaemia.
    Gunn IR; Wallace JR
    Ann Clin Biochem; 1992 Jan; 29 ( Pt 1)():52-8. PubMed ID: 1536526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma.
    Francini G; Petrioli R; Gonnelli S; Correale P; Pozzessere D; Marsili S; Montagnani A; Lucani B; Rossi S; Monaco R; Manganelli A; Salvestrini F; Fiaschi AI
    Cancer; 2001 Sep; 92(6):1468-74. PubMed ID: 11745224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypercalcaemia and breast cancer--an increased humoral component in patients with liver metastases.
    Coleman RE; Fogelman I; Rubens RD
    Eur J Surg Oncol; 1988 Oct; 14(5):423-8. PubMed ID: 2846366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
    Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
    Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary hydroxyproline excretion in early and advanced breast cancer-a sequential study.
    Cuschieri A
    Br J Surg; 1973 Oct; 60(10):800-3. PubMed ID: 4748385
    [No Abstract]   [Full Text] [Related]  

  • 20. Familial hypocalciuric hypercalcaemia: a review.
    Christensen SE; Nissen PH; Vestergaard P; Mosekilde L
    Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):359-70. PubMed ID: 21986511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.